The Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.
This new 1st edition, includes:
- Trends in joint venture deals
- Joint venture agreement structure
- Joint venture contract documents
- Top joint venture deals by value
- Most active joint venture dealmakers
- Comprehensive directory of joint venture deals since 2009
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
The report provides details of joint venture agreements from 2009 to end of August 2014.
The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all joint venture deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.